Thesis
LOQTORZI's commercial trajectory toward $150-200M by 2028 is the thesis; pipeline optionality in casdozokitug and tagmokitug determines whether this becomes a multi-asset story
LOQTORZI (toripalimab-tpzi), approved for recurrent or metastatic nasopharyngeal carcinoma, is the sole revenue engine for Coherus Oncology, with 2025 net revenue of $40.8M and a projected $150-200M peak by 2028. The thesis resolves on whether LOQTORZI achieves that commercial trajectory before cash is exhausted, with mid-2026 casdozokitug Phase 2 data in NSCLC and HCC providing the critical pipeline inflection. Established PD-1 inhibitors—pembrolizumab and nivolumab—dominate the broader IO landscape, and any NPC label erosion or reimbursement pressure would directly threaten the single commercial asset supporting the entire pipeline.
Focus
Casdozokitug Phase 2 HCC data readout with enrollment complete
mid-2026
Bull
If casdozokitug plus toripalimab plus bevacizumab demonstrates a meaningful improvement in PFS or OS over toripalimab plus bevacizumab alone, it would validate IL-27 as a clinically actionable immunosuppressive axis in HCC and differentiate the triplet from the already-approved atezolizumab plus bevacizumab (Tecentriq/Avastin) backbone. Strong data could attract a partnership or licensing deal, extending the cash runway well beyond the current 2026 guidance and reducing reliance on repeated dilutive equity raises.
Bear
The HCC first-line space is already crowded with high-efficacy approved regimens including atezolizumab plus bevacizumab (Roche), durvalumab plus tremelimumab (AstraZeneca's HIMALAYA regimen), and sintilimab plus bevacizumab biosimilar, making it difficult to show incremental benefit; a null or marginal result would raise serious questions about the IL-27 mechanism in HCC and could impair casdozokitug's credibility across other indications. Additionally, even with cash runway extending into Q3 2027 after two equity raises in early 2026, a failed readout could force another highly dilutive financing at a deeply depressed share price.
Unlock the full thesis for CHRS.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.